Yahoo Poland Wyszukiwanie w Internecie

Search results

1. emedicine.medscape.com › article › 779322-treatmentHemophilia A (Factor VIII Deficiency) Treatment & Management

   emedicine.medscape.com › article › 779322-treatment

   • Zapisane w pamięci cache

   18 paź 2015 · The treatment of hemophilia may involve prophylaxis, management of bleeding episodes, treatment of factor VIII (FVIII) inhibitors, and treatment and rehabilitation of...

   • Factor VIII Deficiency

     Factor VIII Deficiency - Hemophilia A (Factor VIII...

   • Questions & Answers

     Questions & Answers - Hemophilia A (Factor VIII Deficiency)...

   • DDx

     DDx - Hemophilia A (Factor VIII Deficiency) Treatment &...

   • Guidelines

     Guidelines - Hemophilia A (Factor VIII Deficiency) Treatment...

   • Acquired Hemophilia

     Acquired hemophilia is a rare but potentially...

   • Hemophilia C

     Hemophilia C (deficiency of factor XI) was described first...

2. www.cdc.gov › hemophilia › treatmentTreatment of Hemophilia | Hemophilia | CDC - Centers for Disease...

   www.cdc.gov › hemophilia › treatment

   • Zapisane w pamięci cache

   15 maj 2024 · Roctavian™ is a gene therapy that was approved by the FDA on June 29, 2023, for the treatment of severe hemophilia A (factor VIII deficiency) in adults. Roctavian™ is made of a virus modified to carry a gene for clotting factor VIII.

3. ashpublications.org › 4108 › 30055How we choose factor VIII to treat hemophilia

   ashpublications.org › 4108 › 30055

   • Zapisane w pamięci cache

   3 maj 2012 · Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy: International Kogenate-FS Study Group. Thromb Haemost 2000

4. haematologica.org › article › viewInternational recommendations on the diagnosis and treatment of...

   haematologica.org › article › view

   • Zapisane w pamięci cache

   Acquired hemophilia A (AHA) is characterized by neutralizing autoantibodies, called inhibitors, against factor VIII (FVIII). 1 AHA is a rare disorder, affecting men and women of all ages. 2 Two peaks in AHA incidence are typically observed; one associated with pregnancy, and another with older age (>60 years old).

5. pmc.ncbi.nlm.nih.gov › articles › PMC2697540Recombinant factor VIII in the management of hemophilia A:...

   pmc.ncbi.nlm.nih.gov › articles › PMC2697540

   For severe hemophilia A, current optimal treatment should have two goals: first, to provide sufficient factor VIII to prevent spontaneous bleeding, and second, to provide sufficient factor VIII to have normal coagulation function after any trauma.

6. ashpublications.org › blood › articleNew therapies for hemophilia - American Society of Hematology

   ashpublications.org › blood › article

   • Zapisane w pamięci cache

   31 sty 2019 · Novel FVIII products. The plasma half-life of the standard therapies for hemophilia requires frequent administration within prophylaxis regimens. These are typically given 3 times per week to every other day for FVIII and 2 or 3 times per week for FIX.

7. www.bleeding.org › bleeding-disorders-a-z › typesHemophilia A - National Bleeding Disorders Foundation

   www.bleeding.org › bleeding-disorders-a-z › types

   • Zapisane w pamięci cache

   Most treatments for hemophilia A focus on replacing the missing protein, FVIII (8), so a person can form a clot, and so reduce or eliminate the bleeds associated with the disorder. Treatments that work to prevent bleeding through new mechanisms have recently come to the market or are undergoing evaluation in research studies.